Robin Kleinert

Mr. Robin Kleinert

Paul-Ehrlich-Institute, Langen, Germany
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
MDMarina Danalache
Marina Danalache
RKRobin Kleinert
Robin Kleinert
JSJ. Schneider
J. Schneider
AEA.L. Erler
A.L. Erler
MSM. Schwitalle
M. Schwitalle
UHUlf Krister Hofmann
Ulf Krister Hofmann

17 October 2019 in Viruses
Verified
Journal Article
Open access
PDF file
RKRobin Kleinert
Robin Kleinert
EMEduardo Montoya-Diaz
Eduardo Montoya-Diaz
TKTanvi Khera
Tanvi Khera
KWKathrin Welsch
Kathrin Welsch
BRBirthe Reinecke
Birthe Reinecke
Richard John Philip BrownRichard John Philip Brown
Richard John Philip Brown
Yellow fever virus (YFV) represents a re-emerging zoonotic pathogen, transmitted by mosquito vectors to humans from primate reservoirs. Sporadic outbreaks of YFV occur in endemic tropical regions, causing a viral hemorrhagic fever (VHF) associated with high mortality rates. Despite a highly effective vaccine, no antiviral treatments currently exist. Therefore, YFV represents a neglected tropical disease and is chronically understudied, with many aspects of YFV biology incompletely defined including host range, host–virus interactions and correlates of host immunity and pathogenicity. In this article, we review the current state of YFV research, focusing on the viral lifecycle, host responses to infection, species tropism and the success and associated limitations of the YFV-17D vaccine. In addition, we highlight the current lack of available treatments and use publicly available sequence and structural data to assess global patterns of YFV sequence diversity and identify potential drug targets. Finally, we discuss how technological advances, including real-time epidemiological monitoring of outbreaks using next-generation sequencing and CRISPR/Cas9 modification of vector species, could be utilized in future battles against this re-emerging pathogen which continues to cause devastating disease.